Clinical trials: Squamous Cell Carcinoma of the Neck
Carcinoma, Squamous Cell
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
- Trial name
- NCT02254044
- Testing
- bivatuzumab mertansine
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps
Patients undergoing free flap reconstructive surgery at University of California, Davis Medical Center (UCDMC) will be assigned randomly into no intervention group (immediate post operative care in an ICU) or intervention group…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Trauma
- Trial name
- ICU (NCT03340038)
- Testing
- Non-ICU Specialty ward
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, Davis
Esophageal Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002884
- Testing
- chemotherapy, cisplatin, fluorouracil
- Where
- France
- Volunteers
- 326 people
- Sponsor
- Centre Hospitalier Lyon Sud
Neoplasms, Head and Neck
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with head and neck cancer following surgery.
- Trial name
- NCT00424255
- Testing
- Lapatinib, Chemoradiation
- Where
- 117 sites in United States, Argentina and 20 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Head and Neck Squamous Cell Carcinoma
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who…
- Trial name
- IMplus (NCT04440917)
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as specialized types of magnetic resonance imaging (MRI), may help in planning radiation therapy that does less damage to normal tissues.
- Trial name
- NCT00984074
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
- Trial name
- NCT03524326
- Testing
- Lenvatinib Pill, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00520091
- Testing
- CPT- 11, Cisplatin, Celecoxib
- Volunteers
- 14 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
The purpose of the study is to assess in a randomized, double blind, controlled, multi-center, phase III study, the efficacy of low level diode laser (100 MW, 658 Nm), in the prevention and treatment of radiochemotherapy-induced…
- Conditions
- Oral Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx, Oral Mucositis
- Trial name
- LaserMucite (NCT01772706)
- Testing
- low level laser therapy
- Where
- 6 sites in France
- Volunteers
- 97 people
- Sponsor
- Institut Cancerologie de l'Ouest
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Xerostomia
Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia
The purpose of this study is to determine the effectiveness of cevimeline (versus placebo) on the oral health of patients who have dry mouth which was caused by radiation therapy that was given for treatment of head and/or neck…
- Trial name
- SMILE (NCT00466388)
- Testing
- Cevimeline
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- American Academy of Otolaryngology-Head and Neck Surgery Foundation
Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured.
- Conditions
- Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- Best Of (NCT02984410)
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS)
- Where
- 32 sites in Belgium, France and 6 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during…
- Conditions
- HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
- Trial name
- NCT07741643
- Testing
- Panitumumab-IRDye800, [18F]NOTA-ABY-030
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in Patients With Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06530914
- Testing
- MRG003 combined with Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin
- Volunteers
- 30 people
- Sponsor
- Lei Liu
Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Neoadjuvant immunochemotherapy can effectively increase the postoperative pathological complete response rate, improve the survival rate of patients, and reduce the risk of recurrence in oral squamous cell carcinoma (OSCC).
- Trial name
- NCT07137858
- Testing
- Preoperative neoadjuvant immunotherapy chemotherapy, Two courses of preoperative neoadjuvant immunotherapy chemotherapy, Three courses of preoperative neoadjuvant immunotherapy chemotherapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Squamous Cell Carcinoma of Head and Neck
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.
- Trial name
- NCT05845307
- Testing
- Control Group, TTI-101
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort…
- Trial name
- NCT05674526
- Testing
- WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allotera Therapeutics
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.